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Purpose: The purpose of this analysis was to assess the 
tumor response and long-term outcome in patients treat-
ed with preoperative radiotherapy (PRT) without systemic 
therapy.
Methods: Between 1997 and 2000, 134 patients with 
non-inflammatory locally advanced breast cancer (LABC) 
were treated with PRT. The tumor dose was 45 Gy in 15 
fractions to the breast and to regional lymph nodes over 
6 weeks. Radical mastectomy was performed 6 weeks after 
PRT to all patients and adjuvant systemic therapy was 
administered as per protocol. The measures of disease out-
come were overall survival (OS) and disease-free survival 
(DFS) which estimated using the Kaplan-Meier method.
Results: Median follow-up was 74 months (range 4-216). 
Objective clinical tumor response after PRT was observed 
in 77.6% of the patients. Clinical complete tumor response 
(cCR) was achieved in 21.6% of the patients. Pathological 
CR in the breast was achieved in 15% of the patients. The 
5- and 10-year OS were 55.1 and 37.8%, respectively. The 5- 
and 10-year DFS were 39.2 and 27%, respectively. Patients 
who achieved cCR had significantly longer OS in compari-
son with patients achieving clinical partial response (cPR) 
and clinical stable disease (cSD). Similarly, DFS of patients 
in the cCR group was longer compared with patients with 
cPR and cSD, yet without statistical significance.
Conclusions: Our results showed that local control in 
LABC patients achieved by primary PRT, followed by radi-
cal mastectomy was comparable with the results reported in 
the literature. Complete pathologic response to PRT identi-
fied a subgroup of patients with a trend toward better DFS 
and OS.
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Radiation therapy (RT) has a very important 
role in the multidisciplinary treatment of differ-
ent stages of breast cancer. RT has been clearly 
demonstrated to reduce locoregional and distant 
relapse after breast conserving surgery (BCS) and 
after radical mastectomy. Moreover, overviews 
by the Early Breast Cancer Trialists Collaborative 
Group (EBCTCG) demonstrates, for the first time, 
that postoperative RT is not only important in 
achieving locoregional control, but also has signif-
icant influence on long-term survival [1-3]. Whole 
breast RT after BCS reduces the 10-year risk of 
any first recurrence (including locoregional and 
distant) by 15% and the 15-year risk of breast can-
cer-related mortality by 4% [2]. Post-mastectomy 
RT in node-positive patients reduces the 10-year 
risk of recurrence by 10% and the 20-year risk of 
breast cancer-related mortality by 8% [3].
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Patients presenting with LABC belong to a het-
erogeneous group of patients with different disease 
outcomes regarding locoregional and distant recur-
rence rates and survival. According to TNM stag-
ing this group includes patients with large prima-
ry tumor, greater than 5 cm (T3) or with skin/chest 
wall involvement (T4), and/or fixed axillary (N2) or 
supraclaviculary lymph nodes (N3), meaning IIIA 
to IIIC disease stages [4-6]. The majority of patients 
with LABC presents with an unresectable tumors 
and have poor prognosis and decreased survival. 
Primary (neoadjuvant) chemotherapy (PCT) 
followed by local therapy, surgery or RT or both, 
has become the standard of care for patients with 
LABC [7-11]. PRT today is indicated after PCT if tu-
mor resectability was not achieved [12,13]. How-
ever, before the introduction of PCT in the thera-
peutic strategy, PRT was more frequently used as 
the sole neoadjuvant approach for initially inop-
erable tumors, in order to reduce tumor volume 
and create a field permitting radical surgery [14-
17]. PRT combined with mastectomy improved lo-
cal and regional control rates, but did not modify 
survival rates. Moreover, in light of the deficient 
PRT’s literature data, the treatment results are in-
conclusive regarding the full benefits of PRT. 
Also, predictive factors for the response to RT 
are less frequently investigated compared to sys-
temic therapy. The neo-adjuvant setting seems to 
be an ideal model for researching the predictive 
value of markers. In our previous analysis [18] a 
limited number of patients in stage III BC, treated 
only with PRT, we have found that 98 genes were 
significantly differentially expressed [False Dis-
covery Rate (FDR) < 0.05] between PRT respond-
ers and non-responders.
The purpose of this analysis was to assess 
the tumor response and long-term outcome in pa-
tients treated with PRT alone, without systemic 
therapy.
Methods
Treatment
Between 1997 and 2000, 134 patients with non-in-
flammatory LABC (stage IIIA and IIIB) were treated 
with PRT at the Institute for Oncology and Radiology 
of Serbia. Radical mastectomy was performed 6 weeks 
after PRT to all patients and adjuvant systemic therapy 
was administered as per protocol.
The staging procedure included the following: 
clinical examination, mammography, chest X-ray, liv-
er sonography, bone scans, complete blood count and 
serum biochemistry. After biopsy of the primary tumor 
and histologically proved breast cancer diagnosis, PRT 
was performed using Cobalt 60 (1,25-MV photons), or 
linear accelerator (6-MV photons). The tumor dose was 
45 Gy in 15 fractions (3 Gy per fraction) every second 
day to the breast and to regional lymph nodes over 6 
weeks. The whole breast was treated through medial 
and lateral tangential fields using wedges to correct for 
inhomogeneity. The dose was prescribed at a point in 
the midplane of the breast. Supraclavicular and axil-
lary nodes were treated through anterior axillary-su-
praclavicular field with calculated doses at the 1/3 of 
the antero-posterior diameter. The internal mamma-
ry nodes were irradiated using a direct anterior filed, 
which covered ipsilateral nodes in the first 3 intercostal 
spaces. Doses were specified at a depth of 2-3 cm. In-
ternal mammary nodes were treated with combination 
of photon beams (30 Gy) and electron beam (15 Gy) in 
order to decrease cardiac toxicity.
Six weeks after the completion of irradiation, radi-
cal mastectomy and axillary nodal dissection were per-
formed to all patients. After mastectomy patients re-
ceived 6 courses of chemotherapy consisting of cyclo-
phosphamide, methotrexate and 5-fluorouracil (CMF) 
or 5-fluorouracil, doxorubicin and cyclophosphamide 
(FAC), and/or endocrine therapy (tamoxifen +/- castra-
tion by irradiation) as per protocol.
Clinical response to PRT in the breast was defined 
according to RECIST criteria [19]: complete response 
(cCR) if there was no palpable tumor in the breast; par-
tial response (cPR) if regression of tumor was more 
than 30%; stable disease (cSD) if tumor regression was 
less than 30% or tumor progression less than 20% and 
progressive disease (cPD) if tumor progression was 
more than 20%. However, patients with cPD were not 
included in this analysis. 
The definition of pathological complete remission 
(pCR) was as follows: pCRB if there was no invasive 
cancer in breast with/without ductal carcinoma in situ 
(DCIS) (yT0 or yTis) and with/without negative region-
al axillary lymph nodes (yN0 or yN1) and total pCR 
(tpCR) if there was pCRB associated with negative re-
gional axillary lymph nodes (yT0 or Tis and yN0). 
Hormone receptors determination
Histology, tumor size and grade, lymph nodes in-
volvement and hormone receptors (HR) status were de-
termined after the definitive surgery from formalin-fixed 
paraffin-embedded (FFPE) invasive breast cancer tissues. 
Hormone receptor contents were prospectively deter-
mined in tumor specimens by classical biochemical dex-
trane-coated charcoal (DCC) method in 81 patients after 
radical surgery [20]. The cut off values to discriminate 
between negative and positive HR status for estrogen 
receptor (ER) and progesterone receptor (PgR) were 10 
fmol/mg protein and 20 fmol/mg protein, respectively. 
Statistics
The primary endpoints of disease outcome were 
Preoperative radiotherapy in locally advanced breast cancer 327
JBUON 2017; 22(2): 327
OS, calculated from the time of tumor biopsy until the 
time of death from any cause, and DFS defined as the 
time from radical surgery until the time of the first 
locoregional and/or distant disease relapse, or death 
without disease relapse.
OS and DFS curves were estimated using the Ka-
plan-Meier method and univariate statistical analysis 
by log rank test was used to assess the difference in 
time to event (OS/DFS) between the analyzed groups.
Results
The median follow-up of 134 patients (medi-
an age 52.5 years, range 34-71) included in this 
study was 74 months (range 4-216). Patient char-
acteristics are presented in Table 1.
An objective clinical tumor response after 
PRT was observed in 104/134 (77.6%) patients. 
cCR was achieved in 29/134 (21.6%) patients. Six 
weeks after finishing PRT, radical mastectomy 
was performed to all patients. tpCR in the breast 
was achieved in 20/134 (15%) patients and among 
them 10/134 (7.5%) had tpCR (Table 2).
HR status was determined in 81 patients and 
cCR was more frequently associated with patients 
with HR-negative than in patients with HR-posi-
tive tumors (25% vs 15.5%) but this difference was 
not statistically significant (Pearson chi-square 
test, p=0.33) (Table 3).
Adjuvant chemotherapy and/or endocrine ther-
apy were administered after completion of locore-
gional therapy. Seventy-one out of 134 (52.9%) 
patients received chemotherapy: 40/134 (29.8%) 
patients received CMF and 31/134 (23.1%) received 
Table 1. Patient, disease and treatment characteristics
Characteristics n (%)
Number of patients 134 (100)
Age (years)
Median (range) 
Mean (SD) 
≤ 50
> 50
52.5 (34-71)
53.4 (8.9)
59 (44.0)
75 (56.0)
Menopausal status
Premenopausal
Postmenopausal 
58 (43.3)
76 (56.7)
Clinical stage at diagnosis
Stage III A
Stage III B
93 (69.4)
41 (30.6)
Clinical T stage 
T1
T2
T3
T4
4 (3.0)
67 (50.0)
22 (16.4)
41 (30.6)
Clinical N stage 
N0 
N1
N2 
3 (2.2)
13 (9.7)
118 (88.1)
Histology (biopsy)
Ductal 
Lobular
Other
56 (41.8)
33 (24.6)
45 (33.6)
Histologic grade
Grade 1 
Grade 2
Grade 3 
Unknown 
1 (0.7)
86 (64.2)
6 (4.5)
41 (30.6)
Nodal status (after mastectomy)
Negative 
Positive 
23 (17.2)
111 (82.8)
Hormone receptor status
ER-neg/PgR-neg 
ER-pos and/or PgR-pos 
Unknown
35 (26.1)
46 (34.3)
53 (39.6)
Adjuvant systemic therapy
Yes
No
127 (94.8)
7 (5.2)
Kind of adjuvant chemotherapy
CMF 
FAC
No chemotherapy 
57 (42.5)
46 (34.4)
31 (23.1)
Adjuvant endocrine therapy
Tamoxifen
Castration by irradiation
Tamoxifen + castration by irradi-
ation 
No hormonal therapy
3 (2.2)
79 (59.0)
ER: oestrogen receptor, PgR: progesterone receptor, CMF: cyclo-
phosphamide, methotrexate, 5-fluorouracil, FAC: 5-fluorouracil, 
doxorubicin, cyclophosphamide
Table 2. Tumor response to preoperative radiotherapy
Clinical response Pathological response
n (%) n (%)
cCR 29 (21.6) pCRB 20 (15.0)
cPR 75 (56.0) tpCR 10 (7.5)
cSD 30 (22.4) non-tpCR 124 (92.5)
Total 134 (100) Total 134 (100)
cCR: clinical complete response, cPR: clinical partial response, 
cSD: clinical stable disease, pCRB: in-breast pathology complete 
response, tpCR: total pCR
Table 3. Clinical tumor response to preoperative radi-
otherapy according HR status
Clinical 
response to 
PRT 
ER-neg/PgR-neg
n (%)
ER-pos and/or 
PgR-pos
n (%)
p value
cCR 
cPR 
cSD
9 (25)
21 (58.3)
6 (16.7)
7 (15.5)
25 (55.6)
13 (28.9)
0.33
Total 36 (100) 45 (100)
HR: hormone receptor, ER-neg: negative ER status of the prima-
ry, ER-pos: positive ER status of the primary, PgR-neg: negative 
PgR status of the primary, PgR-pos: positive PgR status of the 
primary, PRT: preoperative radiotherapy
44 (32.8)
8 (6.0)
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FAC, 24/134 (17.9%) adjuvant endocrine therapy 
(tamoxifen or castration by irradiation) and 32/134 
(23.9%) patients received combination of chemo-
therapy and endocrine therapy.
At the time of analysis 83 patients (61.9%) de-
veloped disease relapse. The first relapse sites are 
presented on Table 4. 
Eighty three out of 134 patients (61.9%) died: 
67/134 (50%) from breast carcinoma and 16/134 
(11.9%) from other causes. The 5- and 10-year OS 
were 55.1% (95% CI 47-64%) and 37.8% (95% CI 
29-48%), respectively. The 5- and 10-year DFS 
Table 4. Sites of the first disease relapse
Sites of disease relapse n (%)
Locoregional relapse 
Isolated locoregional relapse 
Locoregional relapse plus distant 
mets 
Distant metastases
Bones 
Visceral 
Soft tissues 
Brain 
Multiple distant sites 
24 (17.9)
25 (18.6)
7 (5.2)
3 (2.2)
14 (10.5)
Table 5. OS and DFS according to clinical tumor response to PRT
Clinical response to PRT n OS (mos) (95% CI) p DFS (mos) (95% CI) p
cCR 29 145 (>75)
0.038
110 (>36)
NScPR 75 65 (46-90) 31 (24-51)
cSD 30 71 (34-171) 39 (20-78)
OS: overall survival; DFS: disease-free survival, PRT: preoperative radiotherapy, n: number of patients, mos: months, 95%CI: 95% 
confidence interval, NS: non-significant
Figure 1. Overall survival, all patients.
Figure 3. Overall survival according to clinical re-
sponse to preoperative radiotherapy.
Figure 4. Disease-free survival according clinical re-
sponse to preoperative radiotherapy.
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Figure 2. Disease - free survival, all patients.
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were 39.2% (95% CI 31-48) and 27% (95% CI 19-
36%), respectively. Median DFS and OS for the 
whole group was 39 months (95% CI 26-55) and 
74 months (95% CI 53-117), respectively. These 
results are shown in Figures 1 and 2. 
We also analyzed the disease outcome accord-
ing to the tumor response to PRT. This analysis 
showed that patients who achieved cCR had sig-
nificantly longer OS in comparison with patients 
achieving cPR and cSD (log-rank test, p=0.038) 
(Table 5, Figure 3). Similarly, DFS of patients in 
the cCR group was longer compared with patients 
with cPR and cSD, although this difference did not 
reach statistical significance (Table 5, Figure 4). 
Ten-year OS and DFS in patients with differ-
ent clinical tumor response to PRT were as fol-
lows: 56% and 46% in patients with cCR, 31% and 
22% in patients with cPR and 36% and 16% in pa-
tients with cSD.  
There was a trend toward longer DFS in pa-
tients achieving tpCR compared with patients with 
non-tpCR to PRT. However, although OS in patients 
achieving tpCR was longer compared to patients 
not achieving tpCR (145 vs 70 months), this differ-
ence did not reach statistical significance (Table 
6). 
Discussion
According to current recommendations the 
majority of patients with LABC are treated with 
the combination of PCT, surgery and RT [8,12, 
13,21,22]. Generally, the goal of neoadjuvant 
therapy is to reduce tumor volume and achieve 
resectability to allow for radical surgery. PCT 
usually consists of 6-8 cycles of a combination of 
anthracyclines and taxanes and human epidermal 
growth factor receptor 2 (HER2)-targeted therapy 
in case of HER2 positive BC. However, the indica-
tion for PCT has been extended in large operable 
tumors in order to enable less extensive surgery. 
An update analysis of the first two clinical trials 
(NSABP-B-18 and B-27) designed to compare the 
efficacy of PCT and adjuvant CT in patients with 
large operable tumors showed that preoperative 
therapy is equivalent to adjuvant therapy [23]. The 
role of PRT in this context would be in further 
tumor shrinkage in case of PCT failure to achieve 
resectability.
For decades before the introduction of PCT, 
PRT was usually used as sole preoperative treat-
ment for patients presenting with LABC. In the 
recent literature there is little information on 
the implementation of PRT as single initial ther-
apy in the treatment of LABC. Only few articles 
have reported results of PRT before radical mas-
tectomy and conservative surgery in the last few 
years. Santos et al. published results of PRT for 
203 LABC patients after 26 years of follow-up 
[24]. PRT was performed with tumor dose 45 Gy 
in 25 fractions to the breast, ipsilateral axillary, 
supraclavicular and internal mammary lymph 
nodes. After finishing PRT all patients had radi-
cal mastectomy. Pathological CR in the breast was 
observed in 16% of patients and 10- and 20-year 
local control rates were 90% and 84%, respective-
ly. The 10- and 20-year DFS rates were 49% and 
35%, and the 10- and 20-year OS rates were 56% 
and 41%, respectively. Patients with pCR tended 
to have better DFS (log-rank test, p=0.06) and OS 
(log-rank test, p=0.07) when compared to patients 
with PR or SD.
Another report of PRT followed by conser-
vative surgery for T2 and T3 BC patients was 
presented by  Calitchi E et al. [25]. Seventy five 
patients were treated initially with RT (45 Gy 
in 25 fractions to the breast and regional lymph 
nodes). After tumorectomy a postoperative boost 
to tumor bed of 20 Gy using iridium-192 was per-
formed. Adjuvant chemotherapy and/or endocrine 
therapy were administered after completion of lo-
coregional treatment. In-breast pCR rate was not-
ed in 11% of the patients. After median follow-up 
of 10 years, 47% of the patients developed disease 
relapse, and locoregional relapse rate was noted 
in 12% of the treated patients.
In our group of 134 LABC patients, the pCR 
rate in the breast after PRT was similar (15%) 
compared to the reports in the literature (11–
16%). Relapse of disease was observed in 61.9% of 
our patients, while 7.5% had locoregional relapse. 
The 5-and 10-year OS was 55% and 37.8% respec-
tively, and 5- and 10-year DFS was 39.2% and 
27%, respectively. Our results of the local control 
Table 6. OS and DFS according to pathological response to PRT
Pathological response to PRT n OS (mos) (95% CI) p DFS (mos)(95% CI) p
tpCR 10 145 (>114)
0.096
140 (>39)
0.056
non-pCR 124  70 (50-106)  36 (24-51)
OS: overall survival, DFS: disease-free survival, PRT: preoperative radiotherapy, n: number of patients, mos: months, 95%CI: 95% 
confidence interval, NS: non-significant
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rate are quite similar to both reported studies (10-
year local control rate about 90%). However, the 
relapse rate was somewhat higher, while 10-year 
OS rate was lower in our patients comparing to 
other reported studies. The possible reason for 
this might be the difference in adjuvant system-
ic therapy received after definitive locoregional 
therapy. Also, 88% of the patients in our study had 
initial clinical N2 status, while after mastectomy 
83% had pN-positive disease, which could be an-
other reason for lower OS and DFS compared to 
reported data. Santos et al. reported that initially 
56% of the patients had palpable axillary lymph 
nodes, while 31% were classified as pN0 after PRT 
and mastectomy [24]. In the report of Calitchi et 
al. [25], among 75 analyzed patients only one had 
clinical N2 status. Others were classified as cN0 
(75%) and cN1 (14%). Hence, most of our patients 
had advanced axillary nodal disease (N2) with ex-
pected poor survival. Concerning the association 
of pCR and disease outcome, we noticed that pa-
tients who achieved pCR to PRT had significantly 
better disease outcome.
There are several pathologic response clas-
sification systems after PCT [26,27] but high-
ly accepted criterion for the definition of pCR 
includes no invasive tumor in the breast (yT0) 
and no involved regional axillary lymph nodes 
(yN0). Patients achieving pCR following anthra-
cycline-based PCT experience significantly supe-
rior DFS and OS compared with non-responders 
[23]. pCR rates following standard multi-agent CT 
remain relatively low, ranging from 7-31% [28,29] 
with the exception of patients with HER2-posi-
tive BCs that achieved pCR rates up to 50% when 
treated with HER2 targeted therapy such as tras-
tuzumab and lapatinib [30,31] or trastuzumab and 
pertuzumab [32,33]. 
The achievement of pCR (including residu-
al DCIS in breast) to PCT is a surrogate marker 
of better disease outcome in patents with triple 
negative BCs or HER2 positive BCs, especially in 
HR-negative/HER2-positive BC patients [34]. The 
first investigated predictive factor regarding re-
sponse to PCT was HR status. It was shown that 
patients with invasive lobular carcinoma, the ma-
jority of whom were HR-positive, had the lowest 
response rate but with no influences on disease 
outcome [35]. 
The predictive value of the primary tumor HR 
status for the response to PRT is not precisely es-
tablished. In our analysis tumor HR status did not 
influence the clinical response to PRT although 
non-significantly higher response rate was no-
ticed in patients with HR-negative compared to 
HR-positive BCs (25 and 15%, respectively). Simi-
larly, only 8/10 patients achieving tpCR had their 
HR status determined, and majority of them (5/8 
patients) had HR-negative status of the primary 
tumor (data not shown). We did not divide pa-
tients into various biology BC subtypes groups 
because of the low number of patients.
In our previously reported analysis [18] we 
identified a set of 98 genes significantly differen-
tially expressed (false discovery rate/FDH; p<0.05) 
between responders and non-responders to PRT. 
Ingenuity Pathway Analysis was used to deter-
mine molecular functions significantly associat-
ed with this gene list and included regulation of 
cellular growth and proliferation, cell cycle, cell 
death and survival as top scoring function. Ca-
nonical pathways for G2/M DNA damage check-
point regulation and GADD45 genotoxic stress 
signaling were significantly enriched (FDR<0.05) 
among differentially expressed gene list between 
RT resistant and RT sensitive tumors. However 
this analysis was done on 18 patients only (10 re-
sponders and 8 non-responders). 
Since patients who achieved cCR after PRT 
had better DFS and OS rates compared with pa-
tients with non-cCR, it seems that the achieve-
ment of pCR to PRT might be a surrogate marker 
of better disease outcome in these patients. Also, 
longer OS and DFS in patients achieving cCR com-
pared to patients with no cCR in our analysis are 
in line with the previous observations [9,22,34]. 
Another developed strategy in the treatment 
of LABC is concurrent administration of PCT and 
PRT. Semiglazov et al. conducted a randomized 
phase III trial comparing concomitant PCT/PRT 
with PRT alone in 271 LABC (stage IIB-IIIA) pa-
tients [36]. PCT consisted of thiotepa, methotrex-
ate and 5-fluorouracil, while PRT was performed 
to the breast with a total dose of 60 Gy /2 Gy per 
fraction, and 40 Gy to the regional lymph nodes. 
In-tumor pCR was found in 29.1% of the patients 
in the combined group vs 19.4% in PRT alone 
group (p<0.05). The estimated 5-year OS rates 
in the combined vs PRT alone groups were 86.1 
and 78.3% respectively (log rank test, p>0.05) and 
5-year DFS rates were 81 vs 71.6%, respectively 
(log rank test, p<0.05).
Shanta et al. in their early report [37] also 
compared concurrent PCT/PRT (CMF combined 
with irradiation of the breast and regional lymph 
nodes with dose of 40 Gy in 20 fractions) with PRT 
only. Complete tumor remission in the breast was 
achieved in 42.1% in the PCT/PRT group vs 18.9% 
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in the PRT group. The authors noticed significant 
survival advantage in the combined PCT/PRT 
group. The 5-year DFS was 60.6% in the PCT/PRT 
group vs 47.5% in the PRT alone group (p<0.005). 
The largest report on PCT/PRT combination was 
published also by Shanta et al. [38] who retrospec-
tively analyzed a group of 1117 patients with LABC 
treated concomitantly with PCT consisting of CMF 
or FAC, or 5-fluorouracil, epirubicin and cyclopho-
sohamide (FEC) and PRT with tumor dose 40 Gy 
in 20 fractions to the breast and regional lymph 
nodes. The pCR rate was 45.1%, with a low locore-
gional relapse rate of 7%. The OS rate at 5 and 10 
years was 75.6 and 63.9% respectively, and the cor-
responding rate for DFS was 64.5 and 52.6%, re-
spectively. The best survival rate was seen among 
patients achieving pCR. The authors reported min-
imal toxicities of concurrent PCT/PRT. Interruption 
of RT was minimal (less than 5% of patients), while 
skin morbidity usually consisted of mild to severe 
dry desquamation and hyperpigmentation.
The next report of concurrent PCT/PRT was 
published by Alvarado-Miranda et al. [39] who 
treated 112 LABC patients (stage IIB-IIIB). PCT 
consisted of FAC or AC (doxorubicin, cyclophos-
phamide) followed by concomitant CT/RT (weekly 
mitomycin, 5-FU and dexamethasone or cisplatin, 
gemcitabine and dexamethasone combined with 
irradiation of the breast and regional lymph nodes 
with tumor dose 50 Gy in 5 weeks and boost to the 
residual disease with 10 Gy). The authors reported 
in-breast pCR of 42%, while after mean follow-up 
of 43 months the 5-year DFS and OS rate were 
76.9 and 84.2%, respectively. Only one patient 
had local recurrence. The most frequent adverse 
events were grade 1-2 neutropenia in 32.2% and 
grade 3 radio-epithelitis in 22.4% of the patients.
The concomitant paclitaxel and PRT efficacy 
in 105 LABC patients was also investigated by 
Adams et al. [40]. Paclitaxel was administered for 
10-12 weeks with PRT with a total dose 45 Gy (1.8 
Gy per fraction) to the breast and axillary and su-
praclavicular lymph nodes, with a boost of 14 Gy 
(2 Gy per fraction) on the tumor. pCR and pPR af-
ter PCT/PRT was achieved in 34% of the patients 
and associated with significantly better DFS and 
OS. The median follow-up was 60 months and the 
estimated 5-year DFS and OS rate were 61.4 and 
71.6%, respectively.
Alvarado-Miranda et al. [39] considered also 
the impact of ER expression on pCR rate after neo-
adjuvant treatment. They reported that patients 
with ER-negative BCs were significantly more 
likely to achieve pCR during PCT/PRT compared 
to patients with ER positive-tumors. These find-
ings are similar to the results reported by Adams 
et al. [40]. They found pCR rate of 54% in patients 
with ER-negative BCs vs 18% in patients with 
ER-positive tumors (log rank test, p<0.0001). In 
our group of patients HR content was determined 
in 81/134 (60%) patients. Tumor pCR was more 
frequently achieved in patients with HR-negative 
vs HR-positive BCs, but this difference was not 
statistically significant.
According to presented latest literature data, 
pCR rate in LABC patients is more than 2-fold 
higher in patients treated with combined PCT/
PRT than with PRT alone. OS and DFS rates are 
also higher in patients treated with PCT/PRT com-
bination than PRT alone as well.
Conclusion
Our results showed that local control in LABC 
patients achieved by PRT followed by radical mas-
tectomy was comparable with the results reported 
in the literature. pCR to PRT identified a subgroup 
of patents with a trend toward better DFS and OS. 
Further investigation based on biological markers 
between responders and non-responders to PRT 
are needed to establish the optimal multidisci-
plinary approach and the role of PRT in the com-
bined treatment modality for LABC. According to 
literature the combined PCT/PRT strategy might 
be suitable for patients with inoperable LABC. and 
a successful treatment option. 
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